Entry Point Capital, LLC Blueprint Medicines Corp Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Entry Point Capital, LLC holds 1,289 shares of BPMC stock, worth $114,682. This represents 0.2% of its overall portfolio holdings.
Number of Shares
1,289Holding current value
$114,682% of portfolio
0.2%Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
340Shares Held
62MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$591 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$582 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$523 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$288 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$219 Million8.22% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.31B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...